Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 3interventionalRules rewrite

Phase 3: testing Elecoglipron for Obesity

This study wants to measure the how well it works and safety of elecoglipron compared with dummy treatment (placebo) adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

Official registry: https://clinicaltrials.gov/study/NCT07775404 · AstraZeneca · enrollment listed as 351

What this phase means

Phase 3: this treatment already looked useful in smaller studies. Now it is tested in a large group, often against standard care or a dummy treatment, to see if it should be approved.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Elecoglipron, or Placebo. The registry lists allocation as randomized. This study wants to measure the how well it works and safety of elecoglipron compared with dummy treatment (placebo) adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

They plan to enroll about 351 people at 44 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)

Interventions: Elecoglipron, Placebo

Primary outcome (registry wording): Percent change from baseline to Week 52 in body weight

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Body mass index (body-mass index (BMI)) at screening of:
  • 28 kg/m\^2 or higher, or
  • 24 kg/m\^2 to less than 28 kg/m\^2 with at least 1 weight-related comorbidity
  • Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
  • History of at least 1 self-reported unsuccessful dietary effort to lose body weight
  • Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening

Public study contact (from the registry)

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

44 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseSioux Falls, South Dakota
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.

NCT01793168 · Official ClinicalTrials.gov record · Sanford Health

RecruitingNot a traditional drug phaseSan Antonio, Texas
Not a traditional drug phase: testing Dapagliflozin for Diabetes Mellitus, Type 2

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

NCT02969798 · Official ClinicalTrials.gov record · The University of Texas Health Science Center at San Antonio

FAQ about this NCT record

Is NCT07775404 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07775404?

Phase 3. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07775404?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary